This extension at NIBRT’s existing Dublin site will enhance Ireland’s global position in biopharma manufacturing in the new area of advanced therapeutics, including cell and gene therapies, mRNA-based therapies and other novel vaccines.
The facility includes five research laboratories and two state-of-the-art training suites. PM Group services on the project include concept design, planning, detailed design and support during construction. Construction work has commenced and the extension is expected to be complete and operational in the second quarter of 2023.
Follow the link to learn more
By PM Group